 | | Vol. 14.42 – 3 November, 2023 |
| |
|
|
| Scientists investigated the suitability of the Cyclin K-CDK12 complex as a novel therapeutic approach in prostate cancer using the new covalent CDK12/13 inhibitor THZ531.
[International Journal of Cancer] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors confirmed that glutamate decarboxylase 1 (GAD1) was a hub gene in the progression and development of drug resistance in prostate cancer.
[Cancer Cell International] |
|
|
|
| Transcriptome profiling in androgen receptor-positive prostate cancer cells revealed that nuclear mTOR generally downregulated a subset of the androgen response pathway independently of its kinase activity.
[Molecular Cancer Research] |
|
|
|
| Forkhead box (FOX) S1 knockdown inhibited prostate cancer cell proliferation, invasion, migration, EMT, and tumor growth while increased cell apoptosis.
[Biochemical Pharmacology] |
|
|
|
| Researchers delved at how the natural substance dieckol prevented prostate cancerous cells from proliferating and migrating by blocking the JAK/STAT3 signaling pathway in PC-3 cells.
[Environmental Toxicology] |
|
|
|
| The authors investigated whether luteolin could induce ferroptosis in prostate cancer cells through the transcription Factor EB (TFEB).
[The Prostate] |
|
|
|
| Researchers evaluated the novel function of N-myristoyltransferase to understand the regulation of androgen receptor levels by N-myristoyltransferase in prostate cancer cells.
[The Prostate] |
|
|
|
| Scientists elucidated a potential cuproptosis-related competing endogenous RNA axis small nucleolar RNA host gene 17/miR-29a-3p/glycine cleavage system protein H in prostate adenocarcinoma.
[Heliyon] |
|
|
|
| BRCAT54 was downregulated in prostate cancer and could potentially inhibit cancer cell proliferation by downregulating miR-130b-3p through methylation.
[Journal Of Biochemical And Molecular Toxicology] |
|
|
|
|
| Senescent fibroblasts in the prostatic stroma can exhibit a senescence-associated secretory phenotype in the tumor microenvironment, which can contribute to increased local inflammation, thereby promoting prostate cancer progression and resistance to therapy.
[Nature Reviews Urology] |
|
|
|
|
| Drs. Duane Miller and Ramesh Narayanan, have developed a drug candidate for advanced metastatic prostate cancer that is in its first clinical trial and has received fast-track status from the US FDA, potentially accelerating its clinical development.
[The University of Tennessee Health Science Center] |
|
|
|
|
| December 2 – 6, 2023
Boston, Massachusetts, United States |
|
|
|
|
|
| | Fred Hutchinson Cancer Center – Seattle, Washington, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | University of Southern California – Los Angeles, California, United States |
|
|
|
| | University of Alabama at Birmingham – Birmingham, Alabama, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
